(Q71658835)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

title

Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference

A Pollack

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

G K Zagars

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

A K el-Naggar

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

N H Terry

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

language of work or name

English

0 references

publication date

1 November 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

page(s)

711-718

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

Prostate-specific antigen and external beam radiation therapy in prostate cancer

20 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostate Specific Antigen in the Management of Patients with Localized Adenocarcinoma of the Prostate Treated with Primary Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Flow cytometric analysis of DNA and nuclear protein in paraffin-embedded tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Tumour ploidy and prognosis in carcinomas of the bladder and prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2894%2980213-0

7 January 2021

10.1016/S0090-4295(94)80213-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7526527%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference